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Greater Omentectomy Improves Insulin Sensitivity in Nonobese Dogs
Abstract
Visceral adiposity is strongly associated with insulin resistance; however, little evidence directly demonstrates
that visceral fat per se impairs insulin action. Here, we examine the effects of the surgical removal of the greater
omentum and its occupying visceral fat, an omentectomy (OM), on insulin sensitivity (SI) and β-cell function
in nonobese dogs. Thirteen male mongrel dogs were used in this research study; animals were randomly
assigned to surgical treatment with either OM (n = 7), or sham-surgery (SHAM) (n = 6). OM failed to
generate measurable changes in body weight (+2%; P = 0.1), or subcutaneous adiposity (+3%; P = 0.83) as
assessed by magnetic resonance imaging (MRI). The removal of the greater omentum did not significantly
reduce total visceral adipose volume (−7.3 ± 6.4%; P = 0.29); although primary analysis showed a trend for
OM to increase SI when compared to sham operated animals (P = 0.078), further statistical analysis revealed
that this minor reduction in visceral fat alleviated insulin resistance by augmenting SI of the periphery (+67.7
± 35.2%; P = 0.03), as determined by the euglycemic-hyperinsulinemic clamp. Insulin secretory response
during the hyperglycemic step clamp was not directly influenced by omental fat removal (presurgery 6.82 ±
1.4 vs. postsurgery: 6.7 ± 1.2 pmol/l/mg/dl, P = 0.9). These findings provide new evidence for the deleterious
role of visceral fat in insulin resistance, and suggest that a greater OM procedure may effectively improve
insulin sensitivity.
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Greater omentectomy improves insulin sensitivity in non-obese
dogs
Maya Lottati, Cathryn M. Kolka, Darko Stefanovski, Erlinda L. Kirkman, and Richard N.
Bergman
Department of Physiology and Biophysics, University of Southern California Keck School of
Medicine, Los Angeles, CA
Abstract
Visceral adiposity is strongly associated with insulin resistance; however little evidence directly
demonstrates that visceral fat per se impairs insulin action. Here we examine the effects of the
surgical removal of the greater omentum and its occupying visceral fat, an omentectomy, on
insulin sensitivity (SI) and β-cell function in non-obese dogs. Thirteen male mongrel dogs were
used in the present research study; animals were randomly assigned to surgical treatment with
either omentectomy (n=7), or sham-operation (n=6). Omentectomy failed to generate measurable
changes in body weight (+2%; P=0.1), or subcutaneous adiposity (+3%; P=0.83) as assessed by
magnetic resonance imaging. The removal of the greater omentum did not significantly reduce
total visceral adipose volume (-7.3 ± 6.4%; P=0.29); while primary analysis showed a trend for
omentectomy to increase SI when compared to sham operated animals(P=0.078), further statistical
analysis revealed that this minor reduction in visceral fat alleviated insulin resistance by
augmenting SI of the periphery (+67.7 ± 35.2%; P=0.03), as determined by the euglycemic-
hyperinsulinemic clamp. Insulin secretory response during the hyperglycemic step clamp was not
directly influenced by omental fat removal (pre-surgery 6.82 ± 1.4 vs. post-surgery: 6.7 ± 1.2 pM ·
mg-1 · dl-1, P=0.9). These findings provide new evidence for the deleterious role of visceral fat in
insulin resistance, and suggest that a greater omentectomy procedure may effectively improve
insulin sensitivity.
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INTRODUCTION
Obesity is strongly associated with insulin resistance, a risk factor for a number of chronic
diseases, including type 2 diabetes, cardiovascular disease, and some forms of cancer1. As
first suggested by Vague2, visceral adiposity appears to be a more important determinant of
insulin resistance than subcutaneous adiposity or even overall obesity. Beyond the reported
association, there is limited evidence directly implicating visceral fat per se as a cause of
insulin resistance. Furthermore, the pathophysiologic mechanisms that associate visceral
adiposity with impaired insulin action remain poorly understood.
The deleterious effects of visceral fat may be explained by its unique metabolic properties as
it exhibits substantially higher rates of lipolysis compared with other fat tissue, resulting in
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increased mobilization of free fatty acids (FFAs) directly to the liver 3. In vivo studies
reveal that FFAs impair hepatic glucose production and insulin-mediated glucose uptake by
skeletal muscle in humans4, and thus appear to be an important signal interceding visceral
fat accumulation and insulin resistance. Alternatively, visceral adipocytes are known to
variably secrete numerous proteins and cytokines, including tumor necrosis factor-α (TNF-
α), interleukin-6 (IL-6), and/or reduced adiponectin, and one or more of these latter
molecules may impair insulin action5.
Several investigators have attempted to establish a cause and effect relationship between
central adiposity and insulin resistance by demonstrating that the surgical removal of
visceral fat alleviates insulin resistance. Barzilai et al6 reported that surgical removal of 2
intra-abdominal fat pads, the epididymal and perirenal depots, reversed hepatic insulin
resistance in elderly, obese rats. However, it is problematic to relate these results to other
species, including man, given that adipose drainage of these depots don’t enter the portal
circulation. Therefore, in the present study we have performed a surgical procedure that
specifically removes intra-abdominal fat with portal drainage.
Omentectomy refers to the surgical removal of the whole greater omentum and its
constituent fat. A 2002 study investigating this surgery as a possible treatment for obesity
reported that obese patients undergoing simultaneous adjustable gastric binding (AGB) plus
omentectomy saw a greater, long-term improvement in fasting insulin and glucose than
those who received AGB alone7. However, the specific fluctuations in insulin sensitivity
(SI) and fat redistribution resulting from the surgery remain unclear due to the difficulty in
obtaining frequent, accurate measurements in humans.
Thus, our approach to studying the putative role of visceral fat in the pathogenesis of insulin
resistance is the implementation of an omentectomy in the dog, an animal model reminiscent
of human adiposity and its sequelae. To date, we have described that dogs develop insulin
resistance in response to increased adiposity similarly to humans8-9. Furthermore, this large
animal model allows for repetitive metabolic measurements using the most accurate
diagnostic and imaging techniques. The present study is a metabolic characterization of the
in vivo relationship between visceral fat and insulin action in non-obese dogs.
METHODS
Animals
Thirteen male mongrel dogs (30.5 ± 1.0 kg) were used in the present research study. Dogs
were housed under controlled kennel conditions in the University of Southern California
(USC) Medical School Vivarium and were accepted into the study only if determined to be
in good health. Dogs were presented daily with a diet consisting of 825 grams dry chow
(Prolab Canine/ Laboratory High-Density Canine Diet; PMI Nutrition, Brentwood, MO) and
1 can Purina Pro-Plan Puppy (Nestle Purina PetCare Company, St. Louis, MO). The
experimental procedure was approved by the USC Institutional Animal Care and Use
Committee.
Study Design
Experiments began following two weeks of acclimation to the standard diet and
familiarization with the Pavlov sling. Metabolic assessments were made prior to any surgical
treatment at baseline (pre-surgery) in all dogs to determine adiposity, SI, and β-cell function.
Following pre-testing, dogs underwent omentectomy (OM) or sham-surgery (SHAM), and a
minimum of 16 days were allowed for complete medical recovery, after which all
experimental procedures were repeated (post-surgery). All experiments were randomly
performed with a minimum of 2 days between each protocol.
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Surgery
Dogs were randomly assigned to an experimental group: OM (n=7) or SHAM (n=6)
operation. Surgeries were conducted under general anesthesia, initially induced with
intravenous sodium pentobarbital (0.44 mL/kg; Western Medical, Arcadia, CA) and
maintained with isofluorane (Western Medical).
The omentectomy surgery consisted of two components; implantation of chronic catheters
into the jugular and portal vein, and excision of the whole greater omentum. The sham
surgery consisted of catheter implantation only, but was altogether matched with
omentectomy procedure in surgical incisions, treatment, and length of time. The jugular
catheter was first advanced into the right atrium for sampling of mixed venous blood.
Immediately following an abdominal laparotomy, another catheter was secured in the portal
vein. Subsequently in the omentectomy-animals only, the greater omentum was fully
exposed, blood vessels were ligated and cauterized, and the membrane was excised. The
excised omentum was weighed and frozen for future analysis.
Magnetic resonance imaging (MRI)
Prior to each scan, pre-anesthesia was induced with a subcutaneous injection of
Acepromazine (0.04mg/kg; Bio-ceutic, St. Joseph, MO) and Atropine Sulfate (0.1mg/kg;
Western Medical). Dogs then received intravenous anesthesia consisting of Ketamine HCL
(10mg/kg; Bioniche-Pharma, Lake Forest, IL) and Diazepam (0.2mg/kg; Hospira; Lake
Forest, IL). Thirty 1-cm axial images were obtained using a General Electric 1.5 Tesla
Horizon Magnet (version 5.7) for assessment of body composition. The excised omenta
were similarly scanned; membranes were lined up in series on a head coil, and 0.5-cm axial
slices were obtained over the entire omentum for analysis.
Euglycemic-hyperinsulinemic clamps
With the exception of one dog that did not receive a post-OM clamp, each dog was tested in
a longitudinal manner. Beginning at t=-120 min, a primed intravenous infusion of high-
performance liquid chromatography-purified [3-3H]-D-glucose was started (25μCi bolus +
0.25μCi/min; DuPont-NEN, Boston, MA). At t=0, intravenous insulin (0.75mU*min-1*kg-1;
Lilly, Indianapolis, IN) and somatostatin (1.0μg*min-1*kg-1: Bachem California, Torrance,
CA) was started. A 50% dextrose infusion labeled with [3-3H]-D-glucose (2.0μCi/g) was
variably infused to maintain euglycemia and specific activity. Steady-state was defined as
the final 30 minutes of the clamp. Insulin and [3-3H]-D-glucose samples were collected in
heparinized tubes coated with lithium fluoride (Brinkmann Instruments; Westbury, NY)
containing 50μl EDTA. FFA samples were collected in tubes containing 50μl EDTA and
methyl-paraoxon to suppress in vitro lipolysis. Following centrifugation, plasma was
aliquoted into microcentrifuge tubes and stored as necessary.
Hyperglycemic step clamp
Glucose concentrations were clamped at three sequential steps; 100 mg/dl between t=0 and
60 min, 150 mg/dl between t=60 to 150 min, and 200 mg/dl between t=150 and 240 min.
Plasma samples were obtained every 10 minutes for the entirety of the experiment, and a
variable dextrose infusion was used to clamp glucose at the desired level. Steady-state was
defined as the final 30 minutes of each glycemic step.
Assays
Plasma glucose was measured using the YSI-2700 auto-analyzer (Yellow Springs
Instruments; Yellow Springs, OH). To determine [3-3H]-D-glucose concentration, samples
were counted in Ready-Safe scintillation solution (Beckman liquid scintillation counter,
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Fullerton, CA). Insulin was measured using an enzyme-linked immunoassay kit adapted for
dog plasma in our laboratory (Millipore, St. Charles, MO). FFA concentrations were
analyzed using an in vitro calorimetric assay (NEFA HR-2; Wako Pure Chemical Industries,
Richmond, VA).
Analysis and calculations
Each slice obtained from MRI was analyzed using Scion Image (Version Beta 4.0.2; Scion
Corporation, Frederick, MD), which quantifies fat tissue (pixel values 121-254) and non-fat
tissue (pixel values 20-120). The area of fat tissue in each slice was calculated by dividing
total pixels of fat by the ratio of the total pixels to the known area of each slice. Visceral fat
was defined as the area of fat tissue located within the peritoneal cavity in an 11-cm region
of the thorax identified by the central landmark slice where the left renal artery branches
from the abdominal aorta. Subcutaneous fat was calculated as the total fat in the assessment
region less the visceral fat volume. Greater omental images were similarly analyzed.
The timecourse of endogenous glucose production (EGP) and glucose uptake (Rd) was
calculated using Steele’s model modified with a labeled glucose infusion as detailed in
Finegood et al10. SI-CLAMP was defined as the steady-state exogenous glucose infusion rate
(Ginf) divided by the difference between basal and steady-state plasma insulin times the
steady-state plasma glucose concentration. SI-Rd and SI-EGP were calculated by substituting
the difference between basal and steady-state period Rd and EGP timecourse, respectively
for ΔGinf in the above formula.
β-cell function was defined as the slope of the line relating steady state plasma glucose to
plasma insulin concentrations of each glyceamic step period. Disposition index (DI) was
calculated as the product of SI and the area-under-the-curve of insulin secretion during the
step clamp11.
The Kruskal-Wallis equality-of-populations rank test was used to compare changes in SI
between treatment groups using STATA. We analyzed the effect of treatment (OM or
SHAM) in individual animals by comparing to pre-surgery data using paired t-tests, and the
effect of OM-treatment as compared to SHAM-treatment using unpaired t-tests statistics.
Due to the small sample size, Wilcoxon matched pairs test was additionally performed to
verify the effect of each treatment on SI. All other statistics were performed using Prism
4.03 (Graphpad Software Inc., San Diego, CA). Data are reported as the mean ± SE.
Statistically significance was set at P≤0.05.
RESULTS
Body composition
Neither OM or SHAM significantly altered animals’ body weights (pre- vs. post-surgery;
OM: 28.0±0.8 vs. 28.5±0.7kg, P=0.10. SHAM: 33.6±1.3 vs. 33.2±1.3kg, P=0.5); however,
there was by chance a difference in baseline body weights between treatment groups
(P<0.01; animals were randomly assigned to procedures). To account for this difference, all
relevant calculations account for body weight, and changes in individual animals were
compared to the pre-surgery data. In accordance with the lack of change found in body
weight, MRI analysis revealed that there was no overall significant change in adiposity
resulting from either treatment following surgical recovery (Figure 1A). MRI assessment
revealed that visceral fat in SHAM-treated animals increased 5% (pre: 433.7±44.9, post:
454.0±54.8cm3, P=0.53), while subcutaneous fat did not change (pre: 324.2±50.4, post:
325.7±68cm3, P=0.95; Figure 1B). OM-treated animals exhibited a 3% accumulation of
subcutaneous fat (pre: 224.5±50.0, post: 230.7±2.8 cm3, P=0.83, Figure 1B). It is important
to note that the excision of 122.9 ± 11.7g of greater omental tissue resulted in a small
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7.3±6.4% average reduction in the total MRI-measured visceral adipose compartment (pre-
OM: 353.4±46.0, post-OM: 327.5±45.7cm3, P=0.29). Thus, greater omentectomy surgery in
lean dogs produced virtually no measured change in body composition, signifying the
relatively modest nature of this surgical intervention.
Although we observed an insignificant reduction in the visceral fat depot of OM-treated
dogs, direct quantification of the excised omental membranes revealed that they were
composed of 121.4±11.4cm3 fat tissue. Therefore, although the overall MRI-observed
alteration in adiposity was subtle, the greater omentum scan images confirm that a
noticeable volume of fat was in fact removed (Figure 1C) and the amount was variable
among dogs.
Insulin sensitivity
Dogs exhibited a wide variability in insulin sensitivity (SI) prior to treatment at baseline, and
there were no differences between treatment groups (P>0.25). Kruskal-Wallis equality-of-
populations test revealed a tendency for SI to increase with OM, and to decrease with
SHAM (P=0.078). Despite this negative result, further testing was performed using both
parametric and non-parametric analysis. There was a 63.6±31.5% increase in SI-CLAMP
associated with the removal of greater omental fat (pre-OM: 4.55±0.85, post-OM:
7.45±1.18×104dl·kg-1·min-1·pM-1, P=0.04, Figure 2A), with an upward trend in each
omentectomized dog. In contrast, we observed no change in SI-CLAMP with SHAM-
treatment (pre-SHAM: 6.42±0.75, post-SHAM: 6.33±1.75×104dl·kg-1·min-1·pM-1, P=0.95,
Figure 2A). These findings were supported by non-parametric analysis; Wilcoxon revealed
increased SI with OM-treatment from basal (P=0.031), and no change with SHAM-treatment
(P=0.56). Any individual variability in SI following either OM- or SHAM-surgery was
accounted for by a corresponding alteration in visceral fat volume (linear regression
analysis, P=0.025, Figure 2B).
Hepatic SI (SI-EGP) as assessed from EGP suppression during the clamp did not significantly
change with either treatment (pre- vs. post-surgery; OM: 0.9±0.2 vs.
1.2±0.5×104dl·kg-1·min-1·pM-1, P=0.5. SHAM: 1.2 ± 0.2 vs.
1.1±0.2×104dl·kg-1·min-1·pM-1, P=0.40, Figure 3B). Despite the lack of change in hepatic
sensitivity, we observed improvement in the ability of insulin to augment glucose utilization
in the periphery in the OM-treated animals only; steady-state Rd levels had a tendency to
increase (pre: 10.1±2.1, post: 12.4±1.8mg·kg-1·min-1, P=0.08, Figure 3A). When taken in
combination with decreased steady-state insulin levels (pre-OM: 282.2 ± 24.0, post-OM:
229.1±22.4, P=0.17, Figure 3C), SI-Rd was improved 67.7±35.2% by the surgical removal of
omental fat (from 3.5±0.9 to 5.9±1.3×104dl·kg-1·min-1·pM-1, P=0.03). As expected, there
was no effect of SHAM-treatment on Rd timecourse (Figure 3A), plasma insulin (Figure
3C), or SI-Rd (pre: 5.3±0.5, post: 5.1±1.6×104dl·kg-1·min-1·pM-1, P=0.87). There was no
observed effect of either treatment on FFA suppression by insulin during the clamp (Figure
3D).
Fasting parameters
In the pre-surgery state, there were no differences in fasting insulin or FFAs (P>0.2; Table
1) between treatment groups, and there were no corresponding alterations to OM- vs.
SHAM-treatment in any dog. Baseline levels of glucose uptake and glucose production were
similar between groups (Rd: 2.4mg·kg-1·min-1 for both; EGP: 2.2±0.1 and 2.4±0.2
mg·kg-1·min-1 in OM and SHAM, respectively, P=0.48). Fasting glucose values only
approached significance using the Kruskal-Wallis test (pre-OM: 101±2, post-OM: 97±2,
pre-SHAM 93±1, post-SHAM 94±2), all remained within normal physiologic range. Portal
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vein catheters were implanted for the purpose of measuring fasting plasma markers, but had
poor patency.
β-cell function and DI
We found no measurable effect of omentectomy on β-cell functionality (pre-OM: 6.8±1.4,
post-OM: 6.7±1.2pM·mg-1·dl-1, P=0.9, Figure 4A), and only a tendency for DI to increase
from 41.8±7.7 to 59.5±10.8 (P=0.12; Figure 4C). SHAM-treatment had no effect on β-cell
function (pre: 3.5±0.7, post: 4.4±0.77pM·mg-1·dl-1, P=0.23, Figure 4B), or DI (pre-SHAM:
38.4±5.9, post-SHAM: 45.3±14.5, P=0.55, Figure 4D).
DISCUSSION
A number of epidemiological studies have reported visceral fat per se confers a greater risk
for metabolic and cardiovascular disease than obesity per se12. In spite of the strong
association, the concept that visceral fat is particularly deleterious remains controversial due
to the lack of evidence directly implicating visceral fat in insulin resistance. Abate et al13
contends that truncal fat, whether visceral or subcutaneous, is responsible for the
pathogenesis of insulin resistance, yet it was clearly demonstrated that the surgical
liposuction of abdominal subcutaneous fat failed to improve insulin action14 disputing this
latter claim. Still, animal studies aimed at substantiating the especially detrimental role of
visceral adiposity in insulin action have been unsuccessful due to the challenging nature of
surgically removing “true” visceral fat6 – the mesenteric fat depot-- in rodents. Thus, it
remains to be demonstrated whether visceral fat per se is causative of insulin resistance.
Unlike for the rodent, it is not difficult to surgically remove a “true” visceral fat depot in
large animals, such as by performing an omentectomy in the dog. The amount of fat stored
in the greater omentum can vary widely in normal animals -- from thin and transparent in
lean animals, to thick and solidified with adipose tissue in obese ones. Therefore, in contrast
to other models of extreme weight loss and generalized adipose reduction- bariatric surgery,
low-calorie diets, or pharmacologic supplementation15–omentectomy results in a targeted,
diminutive loss of intra-abdominal fat in non-obese dogs. While the initial analysis of the Si
data only approached significance, on further analysis we found that excision of visceral fat
increased Si by 67% - despite the seemingly small 7% reduction of the visceral fat
compartment. Interestingly, all OM-animals had a net upward rise in SI, although the change
was highly variable among individuals. Sham surgeries in which animals were exposed to
similar surgical stress and treatment had no such overall effect on SI.
Our study uniquely demonstrates that a surgical excision of a mere 122 cm3 of omental fat
improves insulin sensitivity, lending support to the hypothesis that it is the specific
localization of adipose tissue, attributing distinct metabolic significance to fat. The
importance of regional adiposity in determination of insulin action has growing evidentiary
support; it was previously shown that an implantation of adipose cells into the subcutaneous
region of lipoatrophic mice significantly improved insulin action16, while implantation of
adipose cells into the visceral region of nude mice increased TNF-α concentrations,
resulting in insulin resistance17. Despite the accumulating evidence favoring the harmful
nature of visceral fat, we cannot discount that there is communication occurring between the
visceral and subcutaneous fat depots that may be responsible for alterations in insulin action.
For instance, the removal of epididymal and perirenal fat pads in rats has been shown to
alter gene expression in other fat depots18.
We were surprised to find that the excision of omentum enhanced glucose utilization in the
periphery, as indicated by a significant increase in the Rd timecourse during the glucose
clamp, but did not appear to alter insulin’s ability to suppress glucose output. While
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unexpected, the improvement in peripheral but not hepatic SI may be explained in several
ways. The insulin dose given to these normal animals was sufficient to completely suppress
EGP in the omentectomy as well as the sham-operated animals. The liver is more sensitive
to insulin than is skeletal muscle, and by performing a dose-response experiment at lower
insulin concentrations we might have observed a difference in liver sensitivity. Also, it has
been shown by several investigators that much of the effect of insulin to control EGP is
indirect, mediated through lipolysis and/or controlled by the central nervous system19-20;
therefore omentectomy may not be particularly effective in altering insulin’s indirect effect.
It is also feasible that changes in hepatic SI would have been detectable previous to the three
weeks allowed for recuperation from surgery, and that the resulting improvement in
peripheral insulin action was a secondary modification. Finally, our data shows that greater
omental fat content per se, versus other intraabdominal fat tissue (i.e. mesenteric,
retroperitoneal), may perhaps directly influence skeletal muscle, though as yet a mechanism
for this is not clear.
It is possible that alterations in SI associated with central adiposity are a result of intricate
communication between the insulin-sensitive organs, and a number of moieties secreted by
visceral adipocytes may mediate changes in insulin action. Among such secretagogues, it is
widely believed that FFAs intercede visceral fat accumulation and insulin resistance21, as
FFA elevations have been shown to stimulate tyrosine-kinase activity, and reduce
autophosphorylation of the insulin receptor in liver and muscle in animals22. In our study,
we did not observe a change in fasting FFA, or insulin-mediated suppression of FFA during
the clamp associated with an omentectomy.
Other secretory products of adipocytes, including TNF-α, interleukin-6, and MCP-1, are
believed to link inflammation and insulin resistance23, and although the mechanism is
poorly understood, activation through JNK, IKKβ, and NF-κB pathways have been
suggested24. Karin and colleagues25 have recently shown that disabling the inflammatory
pathway by knocking out JNK-1, and inducing obesity with a high-fat diet, attenuated the
development of insulin resistance in mice, proving that obesity without inflammation will
not produce insulin resistance. The greater omentum is a highly vascularized membrane
abundant with macrophages and lymphoid structures26, and therefore it is possible that its
excision may reduce the inflammatory response by occupying immune cells, profoundly
improving SI without a change in adiposity. Animals in the present study had chronic
indwelling catheters that were exteriorized at the neck, and the persistent opening in the skin
potentially causes an elevated inflammatory response that confounds measurements of
inflammation. Future studies will investigate the role of adipokines in insulin resistance.
Other possibilities that should be investigated include elevated portal vein FFAs and altered
secretion of incretin moieties. One or a number of these factors may be involved in the
improvement of peripheral insulin action associated with visceral adipose reduction.
Some investigators believe that visceral obesity impairs insulin secretion, purportedly due to
elevated portal vein FFA concentrations that may overload the β-cell and impair fatty acid
oxidation27. Our study demonstrated that a rather modest reduction in visceral fat does not
alter the insulin secretory response in healthy individuals, indicating no significant direct
effect of visceral fat removal on pancreatic β-cell function. Conversely, it is possible that we
did not extract sufficient visceral fat to prompt a response from the β-cell, or that
measurements of glucose-stimulated insulin secretion may have been taken too shortly after
surgical treatment. Jimenez et al28 previously showed that SI, secretion, and clearance all
reverted to healthy levels following gastric restrictive surgery, but that the change in insulin
secretion occurred subsequent to all other changes.
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In conclusion, our findings indicate that the regional distribution of fat per se may be a
critical feature conferring the metabolic consequence of adipose tissue, and that a rather
minimal reduction in visceral fat by an omentectomy may result in an improvement in SI,
suggesting that visceral fat may indeed cause insulin resistance.
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FIGURE 1. Effect of surgical treatment on adiposity
(A): Abdominal MRI images of representative dogs from OM and SHAM treatment groups.
Fat tissue appears yellow while all other tissue appears red. Visceral fat is located within the
peritoneal cavity, while subcutaneous fat is outside of the peritoneum. (B): Relative changes
in visceral and subcutaneous adiposity in OM and SHAM-treated dogs. (C) Axial MRI
images of excised omentum from OM-treated dogs.
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FIGURE 2. Effect of surgical treatment on insulin sensitivity
(A) Insulin sensitivity (×104 dl·kg-1·min-1·pM-1) by individual dogs and means ± SE pre-
and post-omentectomy (left panel) and sham (right panel) surgery. (B) Linear regression
depicting the relationship between change in the visceral adipose volume vs. the change in
insulin sensitivity with omentectomy and sham-surgery. *P≤0.05 compared to pre-surgery
by paired t-tests.
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FIGURE 3. Euglycemic- hyperinsulinemic clamp parameters
Time-course data of glucose uptake (A), glucose production (B), plasma insulin (C), and
plasma FFA (D) pre- and post-omentectomy and sham-surgery, respectively. Pre-surgery:
closed symbols. Post-surgery: open symbols. *P≤0.05 compared to pre-surgery by paired t-
tests.
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FIGURE 4. Pancreatic β-cell function
Pre- and post- omentectomy (A) and sham (B) surgery. The disposition index with
omentectomy (C) and sham-treatment (D). Pre-surgery: closed symbols and solid lines;
post-surgery: open symbols and dashed lines.
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Table 1
Effect of surgical treatment on basal parameters
Pre-OM Post-OM Pre-SHAM Post-SHAM
Glucose (mg/dl) 100.2 ± 1.9 97.6 ± 2.4* 92.6 ± 1.2 94.6 ± 1.6
Insulin (pmol/l) 48.6 ± 8.7 48.8 ± 8.2 42.7 ± 8.8 48.9 ± 7.4
Glucose uptake (mg/kg/min) 2.4 ± 0.1 2.5 ± 0.2 2.4 ± 0.2 2.3 ± 0.2
Glucose production (mg/kg/min) 2.2 ± 0.1 2.3 ± 0.2 2.4 ± 0.2 2.2 ± 0.1
FFA (mmol/l) 0.86 ± 0.1 0.84 ± 0.1 0.64 ± 0.1 0.7 ± 0.1
Data are mean ± SE.
*
P <0.05 vs. pre-surgery.
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